Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

65.069

Today's Change

+0.14 (0.21%)

Day's Change

64.43 - 67.78

Trading Volume

2,490,505

Overview

Market Cap

7 Billion

Shares Outstanding

109 Million

Avg Volume

6,455,517

Avg Price (50 Days)

65.84

Avg Price (200 Days)

27.90

PE Ratio

-71.51

EPS

-0.91

Earnings Announcement

24-Apr-2024

Previous Close

64.93

Open

65.70

Day's Range

64.43 - 67.78

Year Range

8.28 - 99.41

Trading Volume

2,532,240

Price Change Highlight

1 Day Change

0.22%

5 Day Change

0.82%

1 Month Change

-6.44%

3 Month Change

203.36%

6 Month Change

510.99%

Ytd Change

255.96%

1 Year Change

205.06%

3 Year Change

932.86%

5 Year Change

677.42%

10 Year Change

713.38%

Max Change

713.38%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment